AVBP

$0.00

(

0.00%

)
Quote details

stock

ArriVent BioPharma, Inc. Common Stock

NASDAQ | AVBP

20.77

USD

0.00

(

0.00%

)

AT CLOSE (AS OF Jul 3, 2025)

$711M

MARKET CAP

-

P/E Ratio

-3.76

EPS

$36

52 Week High

$15

52 Week Low

LIFE SCIENCES

Sector

AVBP Chart

Recent Chart
Price Action
1D
Candles

Trade Smarter

Automate your trading workflow with powerful tools — built for serious traders.

Icon For Time-schedule

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Icon For Search

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Icon For Clipboard-list

Journal

Record your trades and performance to improve your trading with AfterPullback's Trading Journal

AVBP Technicals

Tags:

AVBP Earnings

Yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$94M
Selling General And Administrative $15M
Research And Development $79M
Operating Expenses $94M
Investment Income Net -
Net Interest Income $14M
Interest Income $14M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$80M
Income Tax Expense -$80M
Interest And Debt Expense -
Net Income From Continuing Operations -$80M
Comprehensive Income Net Of Tax -
Ebit -
Ebitda -$80M
Net Income -$80M

Revenue & Profitability

Earnings Performance

AVBP Financials

yearly Balance Sheet (As of Sep 30, 2024)

Field Value (USD)
Total Assets $275M
Total Current Assets $227M
Cash And Cash Equivalents At Carrying Value $74M
Cash And Short Term Investments $74M
Inventory -
Current Net Receivables $500K
Total Non Current Assets $48M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $48M
Short Term Investments $145M
Other Current Assets $15M
Other Non Current Assets -
Total Liabilities $17M
Total Current Liabilities $17M
Current Accounts Payable $3.8M
Deferred Revenue -
Current Debt -
Short Term Debt $324K
Total Non Current Liabilities $14K
Capital Lease Obligations $176K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $176K
Other Current Liabilities $8.3M
Other Non Current Liabilities -
Total Shareholder Equity $258M
Treasury Stock -
Retained Earnings -$238M
Common Stock $3K
Common Stock Shares Outstanding $31M

yearly Cash Flow (As of Sep 30, 2024)

Field Value (USD)
Operating Cashflow -$70M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $187M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$80M

yearly Income Statement (As of Sep 30, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$94M
Selling General And Administrative $15M
Research And Development $79M
Operating Expenses $94M
Investment Income Net -
Net Interest Income $14M
Interest Income $14M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$80M
Income Tax Expense -$80M
Interest And Debt Expense -
Net Income From Continuing Operations -$80M
Comprehensive Income Net Of Tax -
Ebit -
Ebitda -$80M
Net Income -$80M

AVBP News

AVBP Profile

ArriVent BioPharma, Inc. Common Stock Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

None

Discover more tools and features to empower your trading
Explore Features

Quotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.